Recent news and earnings disclosures highlight Molina Healthcare's Q1 2026 financial results, operational challenges, and strategic decisions including the planned exit from the MAPD product.

• Molina Healthcare reported Q1 2026 net income of $14 million, or $0.27 per diluted share, with premium revenue of $10.2 billion and a consolidated medical care ratio of 91.1%, reflecting a challenging medical cost environment [N1][N6].
• The company recorded a $93 million impairment charge in Q1 2026 related to the planned exit of the MAPD product in 2027, impacting intangible assets including contract rights, provider networks, and trade name [N1][S2].
• Membership decreased by 12% year-over-year to 5.0 million as of March 31, 2026, driven by Medicaid market contraction, contract expirations, and Marketplace membership reductions due to product and pricing strategies [N1][N6].
• Liquidity remains strong with cash and cash equivalents of $5.3 billion and short-term investments of $3.9 billion as of March 31, 2026, supporting operational and regulatory requirements [S2].
• The company remains compliant with all financial covenants under its Credit Agreement as of March 31, 2026, with long-term debt of approximately $3.8 billion [S2].

Molina Healthcare’s diversified presence across Medicaid, Medicare, and Marketplace segments provides multiple revenue streams supported by government contracts. The company’s ability to manage medical costs and maintain margins despite rising utilization and acuity levels is a positive operational indicator. Recent acquisitions such as ConnectiCare expand membership and geographic reach. Strong liquidity and compliance with financial covenants support operational flexibility. The company’s strategic decision to exit the MAPD product aligns with focusing on higher acuity dual-eligible populations, potentially improving long-term segment profitability. Ongoing investments in provider networks and technology may enhance service delivery and cost management.

Molina Healthcare faces risks from declining membership due to market contraction and contract expirations, which reduce premium revenue. Medical cost trends have outpaced premium rate increases, leading to elevated medical care ratios and margin compression. The impairment charge related to the MAPD product exit reflects challenges in product alignment and asset utilization. Regulatory capital and dividend restrictions limit financial flexibility at the parent company level. Legal proceedings, including a securities class action, pose potential reputational and financial risks. Increased competition and consolidation in the Medicaid and healthcare sectors may pressure pricing and membership growth. Timing differences in government payments and settlements can impact cash flows and operating results.

Molina Healthcare’s moat is supported by its established presence in government-funded healthcare programs across multiple states, regulatory barriers to entry, and its scale in managing a large member base of approximately 5.0 million. The company’s expertise in navigating complex Medicaid and Medicare regulations, maintaining provider networks, and managing actuarial risk contributes to its competitive position. Regulatory capital requirements and statutory restrictions on subsidiaries create structural barriers for new entrants. Additionally, Molina’s investment-grade portfolio and liquidity management provide financial stability. However, the company faces ongoing challenges from market contraction, medical cost inflation, and regulatory changes that require continuous operational and strategic adaptation.

• Market Contraction and Membership Decline: General market contraction in Medicaid enrollment and expiration of contracts have led to a 12% membership decline year-over-year, impacting premium revenue.
• Rising Medical Costs and Margin Pressure: Medical cost trends and higher utilization, especially in high-acuity populations, have increased the medical care ratio above long-term targets, compressing margins.
• Regulatory Capital and Dividend Restrictions: Statutory capital requirements and regulations restrict the timing and amount of dividends from regulated subsidiaries to the parent company, limiting financial flexibility.
• Legal Proceedings: The company is involved in a securities class action lawsuit alleging violations of federal securities laws related to disclosures and earnings guidance, which could have material adverse effects.
• Product and Strategic Risks: The planned exit from the MAPD product and related impairment indicate challenges in product alignment and asset utilization, requiring strategic adjustments.

• Molina Healthcare, Inc. provides managed healthcare services primarily under Medicaid, Medicare, and state insurance marketplaces (Marketplace) programs across 21 states serving approximately 5.0 million members as of March 31, 2026.
• The company operates four reportable segments: Medicaid, Medicare, Marketplace, and Other (which includes long-term services and supports consultative services and commercial business acquired via ConnectiCare).
• Membership decreased by 12% year-over-year to 5.0 million as of March 31, 2026, driven by general market contraction in Medicaid, expiration of the Virginia Medicaid contract, and a decrease in Marketplace membership due to product and pricing strategy.
• Premium revenue for Q1 2026 was $10.2 billion, a 4% decrease from Q1 2025, reflecting lower membership partially offset by rate updates effective during the quarter.
• The consolidated medical care ratio (MCR) was 91.1% in Q1 2026, up from 89.2% in Q1 2025, indicating increased medical costs relative to premiums.
• General and administrative expenses ratio increased slightly to 7.2% in Q1 2026 from 6.9% in Q1 2025, attributed to timing of operating expenses.
• Net income for Q1 2026 was $14 million, or $0.27 per diluted share, down from $298 million in Q1 2025, impacted by a $93 million impairment charge related to the planned exit of the Medicare Advantage Prescription Drug (MAPD) product in 2027.
• The impairment charge of $93 million relates to intangible assets including contract rights and licenses ($62 million), provider networks ($4 million), and trade name ($27 million) associated with the MAPD product.
• The company’s liquidity position as of March 31, 2026 includes cash and cash equivalents of $5.3 billion, short-term investments of $3.9 billion, total current assets of $13.3 billion, and current liabilities of $8.2 billion, resulting in a current ratio of 1.63 and a cash ratio of 1.13.
• Long-term debt was $3.8 billion as of March 31, 2026, with compliance to all financial covenants under the Credit Agreement.
• The company’s investment portfolio is primarily investment-grade debt securities with maturities under 15 years, managed under board-approved policies to preserve capital and liquidity.
• Premium revenue and medical margins vary by segment: Medicaid premium revenue increased 5% in 2025 with an MCR of 91.8%, Medicare premium revenue increased 13% with an MCR of 92.4%, and Marketplace premium revenue increased significantly with an MCR of 90.6% in 2025.
• The company faces challenges including market contraction in Medicaid enrollment, higher medical cost trends outpacing premium rate increases, and regulatory capital and dividend restrictions on subsidiaries.
• Molina Healthcare’s regulated health plan subsidiaries must maintain minimum statutory capital and surplus levels, which restrict the timing and amount of dividends to the parent company.
• The company’s operating cash flows were negative in 2025 due to timing differences in government agency settlements and a decline in operating income, while investing activities generated positive cash flow mainly from investment sales.
• Molina Healthcare is subject to legal proceedings including a securities class action filed in October 2025 related to disclosures and earnings guidance.
• The company’s key customers include state Medicaid managed care programs, with California, Texas, and Washington each representing at least 10% of total premium revenue in 2025.
• The company’s chief executive officer is the chief operating decision maker and uses revenue, margin, and MCR metrics to assess segment performance and allocate resources.